Current Research Studies

Cancer – PNOC-007: H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

Condition or Therapy:

Cancer and tumors, diffuse intrinsic pontine glioma, glioma, diffuse midline glioma (H3 K27M-mutant), Nivolumab, K27M peptide

Category:

Cancer and Blood Disorders
Study Number: PNOC-007

What is the goal of this study?

The goal of this phase1/2 study is to assess the number of patients with adverse events related to treatment and overall survival at 12 months.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are 3 to 21 years old, and
  • Are newly diagnosed with DIPG, positive for the H3.3K27M mutation (positive testing in CLIA laboratory), and who underwent standard radiation therapy
  • Are newly diagnosed with glioma other than DIPG who are positive for the H3.3K27M mutation (positive testing in CLIA laboratory) including spinal cord gliomas and who underwent standard radiation therapy
  • Are newly diagnosed with DIPG or midline glioma other than DIPG (excluding spinal cord gliomas) who are positive for the H3.3K27M mutation (positive testing from a CLIA or equivalent laboratory required)  and who underwent standard radiation therapy

What will happen if my child takes part in this study?

You can read more about this study at clinicaltrials.gov.

Who can I contact for more information?

To learn more, call (206) 987-2106 or email the study coordinator.


Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Sarah Leary
Research Center: Center for Clinical and Translational Research